FDA let artificial-blood trials continue despite risks

A report that pools data from 16 studies concludes that the FDA should have halted research years earlier because of increased incidence of heart attacks and deaths. Despite evidence that a group of experimental blood substitutes nearly tripled the risk of heart attacks and caused a 30% increase in deaths, the Food and Drug Administration continued to approve some clinical trials of the products, researchers said Monday.

Read the whole article on LA Times - Science

More from LA Times - Science